

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

NCT07100210

| | |
|------------|----------------|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Xingchen Peng |
| Enrollment | 6 participants |

Key Eligibility Criteria

Inclusion (8)

- Male or female patients: aged e 18 years old and d 70 years old;
- Patients with histopathologically confirmed, refractory to second-line treatment, advanced recurrent/metastatic malignant solid tumors and without standard clinical treatment regimens (such as patients with advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.);
- Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1;
- Expected survival time e 3 months;
- More than 28 days since the last chemotherapy/radiotherapy/surgery;
- ... and 3 more (see full listing online)

Exclusion (12)

- Have participated in other drug clinical trials within 4 weeks;
- The tumor is located close to major blood vessels or the trachea;
- Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart failure of NYHA class II or above, unstable angina pectoris, having had a myocardial infarction within 1 year, and having clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.
- For female subjects: pregnant or lactating women.
- Patients have active tuberculosis, bacterial or fungal infections (e grade 2 of NCI-CTCAE 5.0); have active HIV infection, active HBV infection, or HCV infection.
- ... and 7 more (see full listing online)

Locations (1 total)

West China Hospital of Sichuan University, Chengdu, Sichuan, China